Search

Displaying results 9661 - 9670 of 10000 in total
  1. Drug

    ASP-8731

    go.drugbank.com/drugs/DB17696
    Investigational

    ASP-8731 is a novel BACH1 inhibitor that potentially induces fetal hemoglobin (HbF). Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093]

  2. Drug

    DTX-101

    go.drugbank.com/drugs/DB17699
    Investigational

    It was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.[L46103]

  3. Drug

    BBM-H803

    go.drugbank.com/drugs/DB17700
    Investigational

    BBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed and manufactured by Belief BioMed.

  4. Drug

    WP-1301

    go.drugbank.com/drugs/DB17702
    Experimental

    WP1301 is a synthetic peptide derived from hFVIII. It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]

  5. Drug

    Coagulin-B

    go.drugbank.com/drugs/DB17703
    Experimental

    Coagulin-B is an adeno-associated viral vector expressing human blood-coagulation Factor IX. … [A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation

    Synonyms: Coagulin B, Coagulin-B
  6. Drug

    BBM-H901

    go.drugbank.com/drugs/DB17704
    Investigational

    BBM-H901 is a liver-tropic adeno-associated viral (AAV) vector carrying cassette coding hyperactive Padua factor IX (FIX) protein. It is being investigated for the treatment of hemophilia B.[A259048]

  7. Drug

    Dalcinonacog alfa

    go.drugbank.com/drugs/DB17707
    Investigational

    Dalcinonacog alfa is a recombinant human factor IX (FIX) variant. It is being investigated for the treatment of hemophilia B.[A259058]

  8. Drug

    SIG-007

    go.drugbank.com/drugs/DB17710
    Experimental

    SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A. … Developed by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.[L46153]

  9. Drug

    TT 173

    go.drugbank.com/drugs/DB17717
    Investigational

    TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental

  10. Drug

    Marstacimab

    go.drugbank.com/drugs/DB17725
    ApprovedInvestigational

    Marstacimab is a human monoclonal immunoglobulin G Type 1 (IgG1) antibody produced by Chinese hamster ovary (CHO) cells by recombinant DNA technology. … [L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant.

    Synonyms: Immunoglobulin g1, anti-(human tissue factor pathway inhibitor) (human monoclonal pf-06741086 .gamma.1-chain), disulfide with human monoclonal pf-06741086 .lambda.-chain, dimerProducts: Hympavzi 150 mg/mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem (1 adet)